"Fairest of them all" for myelodysplastic syndromes

Blood

Volumn 111, Issue 1, 2008, Pages 6-

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MYELODYSPLASTIC SYNDROME; NOTE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 38049170909     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-10-115980     Document Type: Note

References (4)

1. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037-1046.
2. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity inMDSpatients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21:1436-1441.
3. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903.
4. Kantarjian H, Issa J-P, Rosenfeld CR, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106:1794-1803.